Copyright
©The Author(s) 2017.
World J Gastroenterol. Feb 28, 2017; 23(8): 1489-1496
Published online Feb 28, 2017. doi: 10.3748/wjg.v23.i8.1489
Published online Feb 28, 2017. doi: 10.3748/wjg.v23.i8.1489
Figure 4 Comparisons of infliximab trough levels and antibody to infliximab levels in patients with/without immunomodulators.
There were no differences in the median infliximab trough level (IFX-TL) (0.632 μg/mL and 1.150 μg/mL, respectively; P = 0.274) (A) and median antibodies to infliximab (ATIs) (8.655 AU/mL and 9.017 AU/mL, respectively; P = 0.083) (B) levels between the 2 groups according to the use of concomitant immunomodulators.
- Citation: Oh EH, Ko DH, Seo H, Chang K, Kim GU, Song EM, Seo M, Lee HS, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK, Park SH. Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease. World J Gastroenterol 2017; 23(8): 1489-1496
- URL: https://www.wjgnet.com/1007-9327/full/v23/i8/1489.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i8.1489